Skip to content

Focus-out Glasses on Emmetropization in Chinese Children

Effect of Peripheral Focus-out Glasses on Emmetropization in Chinese Children Aged 6-8 Years: 2 Years Randomized Clinical Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05689567
Enrollment
160
Registered
2023-01-19
Start date
2023-03-23
Completion date
2026-03-31
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emmetropization, Hyperopia, Myopia

Brief summary

The purpose of this study is to characterize the effects of peripheral focous-out glasses on emmetropization in non-myopic Chinese Children Aged 6-8 Years.This is a prospective, parallel-controlled randomized trial.

Detailed description

Myopia is one of the most common eye diseases that cause visual impairment and blindness, and the high rate of myopia in young people is a major public health issue. Based on the clinical studies of optical defocusing to regulate eye growth and refractive changes through visual signal feedback, we hypothesize that early wearing of peripheral defocus glasses in children can slow down the process of emmetropization and even prevent the onset of myopia by producing more myopic defocusing. The aim of this study is to investigate whether wearing peripheral defocus glasses can effectively delay emmetropization in non-myopic children aged 6-8 years , and to further explore its effect on preventing the onset of myopia. The study adopts a 2-year,single-centre, randomized, parallel-controlled trial with a non-blinded design. Subjects who pass the screening period will have their baseline data collected and will be assigned to the experimental or control groups according to the randomization principle. The experimental group will be fitted with Direct Emmetropia with Focus-out Glasses (hereafter referred to as DEFOG) to guide the emmetropization process. The control group will be given no treatment and will be a blank control. Baseline data including visual acuity, cycloplegic objective refraction, axis length, accommodation amplitude, strabismus examination, pupil size, choroidal thickness and peripheral retinal refraction will be measured when enrolled in the group and follow-up data will be measured at month 6, 12, 18 and 24. The primary interest of this study will be studied by comparing the difference in cycloplegic objective refraction changes between month 24 and baseline in the two groups of subjects.

Interventions

DEVICEDEFOG glasses(peripheral focus-out glasses)

Subjects in the intervention group will wear peripheral focus-out glasses ≧8 hours a day and ≧5 days a week.

Sponsors

Children's Hospital of Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 8 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age: ≥6 and ≤8 years at enrollment. 2. At least one parent' s Spherical equivalent refraction≤-3.00D. 3. Spherical equivalent refractions (SERs) under cycloplegia: +0.50 to +1.50 diopters (D) 4. Astigmatism ≤1.00 D . 5. Anisometropia ≤1.00 D. 6. Best Corrected Visual Acuity (BCVA) : 1.0 or better 7. Provision of consent written by subject's legal guardian 8. Willing and able to participate in all required activities of the study

Exclusion criteria

1. Any of the following abnormalities on the ocular surface, such as trachoma, pemphigoid, chemical injury, heat burn, radiation injury, etc. 2. Eyelid abnormalities (e.g. entropion, ectropion, tumor, edema, blepharospasm, incomplete eyelid closure, severe trichiasis, severe ptosis) ,which affect eyelid function in either eye 3. Eye diseases such as strabismus, amblyopia, anisometropia, fundus diseases, and accommodation abnormality,etc. 4. Prior treatment of myopia control in either eye, including but not limited to drugs, orthokeratology, low-level red-light therapy, etc. 5. Noncompliance with measurement at enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Overall Changes of Cycloplegic Objective Refraction(spherical equivalent refraction, SER)(D)From baseline till the 24th monthChanges of cycloplegic objective refraction(i.e reflected by SER) from baseline till the 24th month (only the right-eye data included). Objective refraction data will be examined by AUTO REF/KERATOMETER. Ciliary muscle paralysis will be performed by using 1% cyclopentanone eye drops, 2 doses in each eye, 2 doses 5 minutes apart. The optometry will be performed after 20 minutes of complete ciliary muscle paralysis (disappearance of pupil response to light or pupil diameter at least greater than 6 mm). SER is calculated by adding the sum of the sphere power with half of the cylinder power. Baseline data will be measured at the time of enrollment. Follow-up data will be measured on the 24th month from baseline. The 24th month data will be subtracted from the baseline data to obtain changes.

Secondary

MeasureTime frameDescription
Changes of Cycloplegic Objective Refraction(SER) (D)The 6th month, the 12th month and the 18th month from baselineChanges of cycloplegic objective refraction (i.e reflected by SER) different follow-up time and the baseline time (only the right-eye data included). Objective refraction data will be examined by AUTO REF/KERATOMETER.
MyopiaThe 6th month, the 12th month, the 18th month and the 24th month from baselineCycloplegic SER≦-0.50D at any follow-up time. Objective refraction data will be examined by AUTO REF/KERATOMETER.
Changes of Axial Length(AL)(mm)The 6th month, the 12th month, the 18th month and the 24th month from baselineChanges of Axial Length (AL) between different follow-up time and the baseline time (only the right-eye data included).AL will be examined by IOL Master.
Amplitude of Accommodation (AMP)(D)The 6th month, the 12th month, the 18th month and the 24th month from baselineAmplitude of Accommodation (AMP) at any follow-up time (only the right-eye data included). AMP will be examined by lens test.
Uncorrected Visual AcuityThe 6th month, the 12th month, the 18th month and the 24th month from baselineThe Logarithmic Visual Acuity at any follow-up time (only the right-eye data included).
Strabismus Examination(△)The 6th month, the 12th month, the 18th month and the 24th month from baselineStrabismus examination at any follow-up time by SYNOPTOPHORE.
Changes of Choroidal Thickness (ChT) (um)The 6th month, the 12th month, the 18th month and the 24th month from baselineChanges of Choroidal Thickness (ChT)between different follow-up time and the baseline time (only the right-eye data included). ChT will be examined by OPTICALCOHERENCETOMOGRAPHY.
Pupil size(mm)The 6th month, the 12th month, the 18th month and the 24th month from baselinePupil size at any follow-up time (only the right-eye data included).
Peripheral Retinal Refraction(D)The 6th month, the 12th month, the 18th month and the 24th month from baselinePeripheral Retinal Refraction at any follow-up time (only the right-eye data included). Peripheral Retinal Refraction will be examined by AUTO FUNDUS CAMERA.
The percentage of participants with fast myopic shiftFrom baseline till the 24th monthThe percentage of participants with fast myopic shift over 2 years(only the right-eye data included). The fast myopic shift is defined as cycloplegic objective refraction (i.e reflected by SER) myopic shift of at least 1.00 D. Objective refraction data will be examined by AUTO REF/KERATOMETER.
Corneal curvature(D) or radius of curvature(mm)The 6th month, the 12th month, the 18th month and the 24th month from baselineCorneal curvature or radius of curvature(only the right-eye included). They can be interconverted. Data will be examined by AUTO REF/KERATOMETER.
Astigmatism (D)The 6th month, the 12th month, the 18th month and the 24th month from baselineThe adtigmatism at any follow-up time (only the right-eye data included).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026